Dictyota menstrualis (Hoyt) Schnetter, Hörning & Weber-Peukert (Dictyotales, Phaeophyceae) was studied for the manufacturing of oil-based bioproducts and co-products. Experiments have been carried out to judge the impact of carbon dioxide (CO2) focus, beneath nitrogen (NO3 (-)) limiting and saturation situations, on progress fee (GR), photosynthesis, in addition to nitrate reductase (NR), carbonic anhydrase (CA), and Rubisco actions. As well as, the biochemical composition of D. menstrualis beneath these situations was estimated. GR, protein content material, and N content material in D. menstrualis have been increased in therapies containing NO3 (-), no matter CO2 addition.
Nonetheless, when CO2 was added to medium saturated with NO3 (-), values of most photosynthesis, Rubisco, and NR exercise, in addition to whole soluble carbohydrates and lipids, have been elevated. CA exercise didn’t range beneath the completely different therapies. The fatty acid profile of D. menstrualis was characterised by a excessive content material of polyunsaturated fatty acids, particularly the omega-Three fatty acids, making it a doable candidate for nutraceutical use.
As well as, this species introduced excessive GR, photosynthetic fee, and fatty acid content material, highlighting its financial significance and the potential for completely different biotechnological functions. High quality and security of perishable merchandise reminiscent of meals, pharmaceutics, and biologicals is a continuing concern. Now we have developed a plasmonic thermal historical past indicator (THI) making the most of the localized floor plasmon resonance of gold nanoparticles (AuNPs) synthesized in situ in alginate, a pure polysaccharide. The colour of the THIs turns into extra intense with elevated storage temperature and/or length, with the colour altering from gray to purple with time of publicity at excessive temperature (40°C).
The outcomes counsel that reducing viscosity with rising variety of AuNPs being synthesized within the system, together with aggregation of newly synthesized AuNPs onto bigger ones and their settling are doubtlessly chargeable for the distinct shade change noticed. Using alginate within the THIs additionally facilitates fabricating them as strong hydrogel matrices by including divalent calcium ions. This alginate-AuNPs THI system is tunable by altering its composition to swimsuit completely different time-temperature monitoring eventualities and the color-change response is irreversible. The THI offers a handy, dependable, secure, and cheap means for monitoring the thermal historical past of perishable merchandise with out the necessity for a read-out gadget.
Ionic liquid-tolerant microorganisms and microbial communities for lignocellulose conversion to bioproducts.
Chemical and bodily pretreatment of biomass is a crucial step within the conversion of lignocellulose to biofuels and bioproducts. Ionic liquid (IL) pretreatment has attracted important consideration as a result of distinctive means of sure ILs to solubilize some or all parts of the plant cell wall. Nonetheless, these ILs inhibit not solely the enzyme actions but in addition the expansion and productiveness of microorganisms utilized in downstream hydrolysis and fermentation processes.
Whereas pretreated biomass could be washed to take away residual IL and cut back inhibition, in depth washing is dear and never possible in large-scale processes. IL-tolerant microorganisms and microbial communities have been found from environmental samples and research begun to elucidate mechanisms of IL tolerance. The invention of IL tolerance in environmental microbial communities and particular person microbes has result in the proposal of molecular mechanisms of resistance. On this article, we assessment latest progress on discovering IL-tolerant microorganisms, figuring out metabolic pathways and mechanisms of tolerance, and engineering microorganisms for IL tolerance. Analysis in these areas will yield new approaches to beat inhibition in lignocellulosic biomass bioconversion processes and improve alternatives for the usage of ILs in biomass pretreatment.
Municipal wastes, be it strong or liquid, are rising as a result of world inhabitants progress and speedy urbanization and industrialization. Typical administration apply involving recycling, combustion, and therapy/disposal is deemed unsustainable. Options should be sought to not solely improve the capability but in addition enhance the sustainability of waste administration. Analysis has demonstrated that the non-recyclable waste supplies and bio-solids could be transformed into useable warmth, electrical energy, or gas and chemical by way of a wide range of processes, together with gasification, pyrolysis, anaerobic digestion, and landfill gasoline along with combustion, and wastewater streams have the potential to help algae progress and supply different vitality restoration choices.
The current assessment is meant to evaluate and analyze the present state of data within the municipal strong wastes and wastewater therapy and utilization applied sciences and suggest sensible resolution choices and future analysis and improvement wants.
Hydraulic retention time results on wastewater nutrient elimination and bioproduct manufacturing through rotating algal biofilm reactor.
Rotating algal biofilm reactor (RABR) know-how was efficiently employed in an efficient technique to couple the elimination of wastewater vitamins with accumulation of priceless bioproducts by grown algae. A secondary stage municipal wastewater was fed to the developed system and the results of the hydraulic retention time (HRT) parameter on each nutrient elimination and bioproduct manufacturing have been evaluated beneath fed-batch operation mode. Two units of bench scale RABRs have been designed and operated with HRTs of two and 6days in an effort to present aggressive atmosphere for algal progress.
Positive control tissue section for each individua |
|||
| Control-Slides-for-each-antibody | Innovex | Set of 25 | EUR 355 |
|
Description: Positive control tissue section for each individual antibody; Based on availability; INQUIRE |
|||
CD11b Antibody Antibody |
|||
| ABD2911 | Lifescience Market | 100 ug | EUR 525.6 |
ASAP1 antibody Antibody |
|||
| DF8746 | Affbiotech | 200ul | EUR 420 |
anti- Antibody^Polyclonal antibody control antibody |
|||
| LSMab09882 | Lifescience Market | 100 ug | EUR 525.6 |
ARHGDIA Antibody / RHOGDI Antibody |
|||
| F54788-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 165 |
ARHGDIA Antibody / RHOGDI Antibody |
|||
| F54788-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 379 |
Antibody |
|||
| A1360-500 | Biovision | each | Ask for price |
Anti-Glycolipid Antibody (AGA) Antibody |
|||
| 20-abx004855 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx008109 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx123734 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx014333 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| abx033330-400ul | Abbexa | 400 ul | EUR 627.6 |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| abx033330-80l | Abbexa | 80 µl | EUR 343.2 |
Anti-Glycolipid Antibody (AGA) Antibody |
|||
| abx036399-100ug | Abbexa | 100 ug | EUR 469.2 |
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319900 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319901 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319905 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319913 | Abbexa |
|
|
Anti-Glycolipid Antibody (AGA) Antibody |
|||
| abx230204-100ug | Abbexa | 100 ug | EUR 577.2 |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx324434 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx311665 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| abx234901-100ug | Abbexa | 100 ug | EUR 661.2 |
Anti-Anti-SEPT6 antibody antibody |
|||
| STJ11100949 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
|||
Anti-Anti-SEPT9 Antibody antibody |
|||
| STJ111369 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
|||
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ111530 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT4 Antibody antibody |
|||
| STJ112276 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
|||
Anti-Anti-MARCH9 Antibody antibody |
|||
| STJ112609 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ113941 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ114081 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT5 Antibody antibody |
|||
| STJ114819 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
|||
Anti-Anti-MARCH8 Antibody antibody |
|||
| STJ114828 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT7 Antibody antibody |
|||
| STJ116214 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
|||
Anti-Anti-SEPT8 Antibody antibody |
|||
| STJ117206 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-SEPT12 Antibody antibody |
|||
| STJ117759 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-MARCH6 Antibody antibody |
|||
| STJ118549 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-MARCH6 Antibody antibody |
|||
| STJ118550 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-MARCH7 Antibody antibody |
|||
| STJ118752 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT3 Antibody antibody |
|||
| STJ118990 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT2 Antibody antibody |
|||
| STJ28365 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT7 Antibody antibody |
|||
| STJ28963 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
|||
Anti-Anti-SEPT2 Antibody antibody |
|||
| STJ25475 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT5 Antibody antibody |
|||
| STJ25477 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
|||
Anti-Anti-SEPT8 Antibody antibody |
|||
| STJ25479 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-SEPT1 antibody antibody |
|||
| STJ119580 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012] |
|||
CLCN5 Antibody / CIC-5 antibody |
|||
| RQ6462 | NSJ Bioreagents | 100ug | EUR 419 |
|
Description: The CLCN5 gene encodes the chloride channel Cl-/H+ exchanger ClC-5. This gene encodes a member of the ClC family of chloride ion channels and ion transporters. The encoded protein is primarily localized to endosomal membranes and may function to facilitate albumin uptake by the renal proximal tubule. Mutations in this gene have been found in Dent disease and renal tubular disorders complicated by nephrolithiasis. Alternatively spliced transcript variants have been found for this gene. |
|||
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
|||
| 48169-100ul | SAB | 100ul | EUR 399.6 |
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
|||
| 48169-50ul | SAB | 50ul | EUR 286.8 |
Anti CD22 Antibody: CD22 Monoclonal Antibody |
|||
| 065-A-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: anti-CD22 monoclonal antibody |
|||
Anti CD22 Antibody: CD22 Monoclonal Antibody |
|||
| 065-A-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: anti-CD22 monoclonal antibody |
|||
Antibody Pair to ApoA-V antibody |
|||
| 10R-1876 | Fitzgerald | 100 ul | EUR 781.2 |
|
Description: Mouse monoclonal Antibody Pair to ApoA-V antibody |
|||
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
| 20-abx103034 | Abbexa |
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
| 20-abx103035 | Abbexa |
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
| 20-abx103036 | Abbexa |
|
|
Hepatitis C Virus Antibody (HCV) Antibody |
|||
| abx023924-1mg | Abbexa | 1 mg | EUR 1446 |
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319902 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319903 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319904 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319906 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319907 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319908 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319914 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319915 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319916 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319929 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319930 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319931 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (HRP) |
|||
| 20-abx311666 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (FITC) |
|||
| 20-abx311667 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (Biotin) |
|||
| 20-abx311668 | Abbexa |
|
|
Anti-Glycoprotein 210 Antibody (gp210) Antibody |
|||
| abx233571-100ug | Abbexa | 100 ug | EUR 577.2 |
Anti Deoxyribonucleic Acid Antibody (DNA) Antibody |
|||
| abx411057-50ug | Abbexa | 50 ug | EUR 710.4 |
Monoclonal NGF/proNGF Neutralizing Antibody Antibody |
|||
| AMM06679G | Leading Biology | 0.05mg | EUR 633.6 |
|
Description: A Monoclonal antibody against Human NGF/proNGF Neutralizing. The antibodies are raised in Mouse. This antibody is applicable in E |
|||
Goat anti- human Antibody^Polyclonal antibody |
|||
| LSMab09896 | Lifescience Market | 100 ug | EUR 525.6 |
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D | Stressmarq | 0.1mg | EUR 424.8 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A390 | Stressmarq | 0.1mg | EUR 481.2 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 390. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A488 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 488. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A565 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 565. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A594 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 594. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A633 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 633. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A655 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 655. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A680 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 680. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A700 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 700. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-ALP | Stressmarq | 0.1mg | EUR 472.8 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Alkaline Phosphatase. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-APC | Stressmarq | 0.1mg | EUR 478.8 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC . |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-APCCY7 | Stressmarq | 0.1mg | EUR 565.2 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC/Cy7. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-BI | Stressmarq | 0.1mg | EUR 475.2 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Biotin. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-DY350 | Stressmarq | 0.1mg | EUR 496.8 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 350. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-DY405 | Stressmarq | 0.1mg | EUR 483.6 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 405. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-DY488 | Stressmarq | 0.1mg | EUR 471.6 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 488. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-DY594 | Stressmarq | 0.1mg | EUR 474 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 594. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-DY633 | Stressmarq | 0.1mg | EUR 468 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 633. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-FITC | Stressmarq | 0.1mg | EUR 470.4 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to FITC. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-HRP | Stressmarq | 0.1mg | EUR 465.6 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to HRP. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-P594 | Stressmarq | 0.1mg | EUR 488.4 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PE/ATTO 594. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-PCP | Stressmarq | 0.1mg | EUR 478.8 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PerCP. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-RPE | Stressmarq | 0.1mg | EUR 476.4 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to RPE . |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-STR | Stressmarq | 0.1mg | EUR 477.6 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Streptavidin. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692S | Stressmarq | 0.012mg | EUR 78 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
|||
Anti-Noelin Antibody BIOTIN Antibody BIOTIN |
|||
| STJ501938 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-Noelin Antibody FITC Antibody FITC |
|||
| STJ501939 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-Noelin Antibody BIOTIN Antibody BIOTIN |
|||
| STJ501940 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-Noelin Antibody FITC Antibody FITC |
|||
| STJ501941 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-IgG1 Negative Control Antibody antibody |
|||
| STJ16100881 | St John's Laboratory | 1 mL | EUR 573.6 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| R20161-100UG | NSJ Bioreagents | 100ug | EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| R20161BTN-50UG | NSJ Bioreagents | 50ug | EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| R20161SAF-250UG | NSJ Bioreagents | 250ug | EUR 979 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| R20179-100UG | NSJ Bioreagents | 100ug | EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| R20179BTN-50UG | NSJ Bioreagents | 50ug | EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| R20179SAF-250UG | NSJ Bioreagents | 250ug | EUR 979 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| RQ4975 | NSJ Bioreagents | 100ul | EUR 419 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V9032-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V9032-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V9032IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V9032SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3151-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3151-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3151CF488-100T | NSJ Bioreagents | 100 Tests | EUR 499 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3151IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3151SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3152-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3152-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3152SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
The HRT considerably affected nitrogen and phosphorus uptakes together with lipid and starch accumulations by microalgae in harvested biofilms. Domination of nitrogen elimination in 2-day HRT with increased lipid accumulation (20% on dried weight foundation) and phosphorus elimination in 6-day HRT with increased starch manufacturing (27% on dried weight foundation) was noticed by evaluating the performances of the RABRs in duplicate runs.